This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    viktoria-1
Previous Study | Return to List | Next Study

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05501886
Recruitment Status : Recruiting
First Posted : August 16, 2022
Last Update Posted : August 1, 2023
Sponsor:
Information provided by (Responsible Party):
Celcuity, Inc.

Brief Summary:
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3

Detailed Description:
This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 701 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
Actual Study Start Date : September 30, 2022
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : September 30, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm A - Patients Lacking PIK3CA Mutations (WT)
Gedatolisib + Palbociclib + Fulvestrant
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
  • PF-05212384
  • PKI-587

Drug: Palbociclib
Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
Other Names:
  • IBRANCE
  • PD-0332991

Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex

Experimental: Arm B - Patients Lacking PIK3CA Mutations (WT)
Gedatolisib + Fulvestrant
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
  • PF-05212384
  • PKI-587

Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex

Active Comparator: Arm C - Patients Lacking PIK3CA Mutations (WT)
Fulvestrant
Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex

Experimental: Arm D - Patients with PIK3CA Mutation (MT)
Gedatolisib + Palbociclib + Fulvestrant
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
  • PF-05212384
  • PKI-587

Drug: Palbociclib
Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
Other Names:
  • IBRANCE
  • PD-0332991

Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex

Active Comparator: Arm E - Patients with PIK3CA Mutation (MT)
Alpelisib + Fulvestrant
Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex

Drug: Alpelisib
Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
Other Names:
  • Piqray
  • Vijoice
  • BYL719

Experimental: Arm F - Patients with PIK3CA Mutation (MT)
Gedatolisib + Fulvestrant
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
  • PF-05212384
  • PKI-587

Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex




Primary Outcome Measures :
  1. Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Approximately 48 months ]
    PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)


Secondary Outcome Measures :
  1. Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From date of randomization to the date of death due to any cause, up to approximately 48 months ]
    OS is defined as the length of time from randomization until the date of death from any cause method, where PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)

  2. Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]
    Percentage of subjects who achieved an objective response according to RECIST v1.1 criteria (complete response [CR] or partial response [PR]) as assessed by BICR)

  3. Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]
    Time from the assessment of initial response (PR or better) to death or first documented disease progression as assessed by BICR, whichever occurs first

  4. Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]
    Time form randomization to the first assessment of PR or better as assessed by BICR, whichever comes first

  5. Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]
    Percentage of subjects with CR, PR, or stable disease (SD) >24 weeks as assessed by BICR

  6. Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]
    The FACT-B TOI is an abbreviated (24-item) version of the full FACT-B which focuses only on the patient's Physical Well-being (PWB), Functional Well-being (FWB), and Breast Cancer Subscale (BCS) components using a 5-level scale, (Not at all, A little bit, Some-what, Quite a bit, Very much).

  7. Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]
    NCCN-FACT is derived from the FACT-B and only 4 additional items will be administered to enable optional scoring of the NFBSI subscales and total score using a 5-level scale (Not at all, A little bit, Some-what, Quite a bit, Very much).

  8. Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]
    Patient-Reported Outcomes Measurement Information System (PROMIS®) Short Form v2.0 - Physical Function 8c using a 5-level scale (Without any difficulty, With a little difficulty, With some difficulty, With much difficulty, Unable to do)

  9. EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]
    EuroQol 5 Dimension 5 Level (EQ-5D-5L) - This is a 5 question, self-administered visual analog scale (VAS) where patients use 0 (worst health) to 100 (best health) to indicate how they view their health.

  10. Adverse Events [ Time Frame: Up to approximately 48 months ]
    Safety and tolerability will be evaluated by review of type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0), seriousness, and relationship to study medications of adverse events (AEs) and any laboratory abnormalities



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study.
  2. Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment
  3. Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards
  4. Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance
  5. Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status
  6. Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  8. Life expectancy of at least 3 months
  9. Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI)
  10. Adequate bone marrow, hepatic, renal and coagulation function

Exclusion Criteria:

  1. History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years
  2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor
  3. Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)
  4. More than 2 lines of prior endocrine therapy treatment
  5. Bone only disease that is only blastic with no soft tissue component
  6. Subjects with type 1 diabetes or uncontrolled type 2 diabetes
  7. Known and untreated, or active, brain or leptomeningeal metastases

    a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment

  8. Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term
  9. History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry

    1. Myocardial infarction within 12 months of study entry
    2. History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months
    3. Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication (initiation or adjustment of antihypertensive medication[s] is allowed prior to screening)
    4. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

      • i. Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, or history of clinically significant/symptomatic bradycardia
      • ii. On screening, inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF >480 msec (determined by mean of triplicate ECGs at screening)
  10. Known hypersensitivity to the study drugs or their components
  11. Pregnant or breast-feeding women
  12. Concurrent participation in another interventional clinical trial

    1. Subjects must agree not to participate in another clinical trial (other than observational) at any time during participation in VIKTORIA-1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05501886


Contacts
Layout table for location contacts
Contact: Nadene Zack, MS 844-310-3900 VIKTORIA-1_TRIAL@CELCUITY.COM

Locations
Show Show 218 study locations
Sponsors and Collaborators
Celcuity, Inc.
Investigators
Layout table for investigator information
Study Director: Nadene Zack Celcuity, Inc.
Layout table for additonal information
Responsible Party: Celcuity, Inc.
ClinicalTrials.gov Identifier: NCT05501886    
Other Study ID Numbers: CELC-G-301
2021-005235-24 ( EudraCT Number )
First Posted: August 16, 2022    Key Record Dates
Last Update Posted: August 1, 2023
Last Verified: July 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celcuity, Inc.:
Breast Cancer, Advanced or Metastatic
gedatolisib
HR Positive
ER Positive
HER2 Negative
PIK3CA MT
PI3K
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Palbociclib
Gedatolisib
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action